| ViP研究评述：延长癌中之王胰腺癌的生存期,任重而道远 |
| |
| 引用本文： | 叶升,高惠冰.ViP研究评述：延长癌中之王胰腺癌的生存期,任重而道远[J].循证医学,2019,19(5):271-272. |
| |
| 作者姓名： | 叶升 高惠冰 |
| |
| 作者单位： | 1. 中山大学附属第一医院肿瘤科, 广州 510080;
2. 广东省人民医院肿瘤中心肿瘤内科、广东省医学科学院, 广州 510080 |
| |
| 摘 要： |
|
| 关 键 词： | 胰腺癌 凡德他尼 吉西他滨 |
Review of The ViP Study： Pancreatic Cancer as The King of Cancer Would Like to Prolong Survival,Yet Has A Long Way to Go |
| |
| YE Sheng,GAO Hui-bing.Review of The ViP Study： Pancreatic Cancer as The King of Cancer Would Like to Prolong Survival,Yet Has A Long Way to Go[J].The Journal of Evidence-Based Medicine,2019,19(5):271-272. |
| |
| Authors: | YE Sheng GAO Hui-bing |
| |
| Institution: | Reviewer's address: Department of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China |
| |
| Abstract: | |
| |
| Keywords: | pancreatic carcinoma Vandetanib Gemcitabine |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
| 点击此处可从《循证医学》下载免费的PDF全文 |
|
